Mpl traffics to the cell surface through conventional and unconventional routes

Traffic

Volumn 15, Issue 9, 2014, Pages 961-982

  Cleyrat, Cédric ^a,b   Darehshouri, Anza ^a   Steinkamp, Mara P ^a   Vilaine, Mathias ^b   Boassa, Daniela ^c   Ellisman, Mark H ^c   Hermouet, Sylvie ^b   Wilson, Bridget S ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b INSERM   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; JAK2; miniSOG; Mpl; MPNs

Indexed keywords

JANUS KINASE 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN MPL; SMALL INTERFERING RNA; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; LAMP1 PROTEIN, HUMAN; LIGHT CHAIN 3, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MPL PROTEIN, HUMAN; SEC31A PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ARTICLE; AUTOPHAGY; BIOTINYLATION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELLULAR DISTRIBUTION; ENDOPLASMIC RETICULUM; ERYTHROLEUKEMIA CELL; EXOSOME; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INTRACELLULAR MEMBRANE; LYSOSOME; MYELOID LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SECRETORY PATHWAY; TRANS GOLGI NETWORK; K562 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MEMBRANE; ENDOPLASMIC RETICULUM; EXOSOMES; HUMANS; JANUS KINASE 2; K562 CELLS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN TRANSPORT; RECEPTORS, THROMBOPOIETIN; VESICULAR TRANSPORT PROTEINS;

EID: 84906324627     PISSN: 13989219     EISSN: 16000854     Source Type: Journal    
DOI: 10.1111/tra.12185     Document Type: Article

References (70)

1. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-3347.
2. de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651-656.
3. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, Eaton DL. Role of c-mpl in early hematopoiesis. Blood 1998;92:4-10.
4. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 2005;280:27251-27261.
5. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996;87:2154-2161.
6. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996;87:567-573.
7. Tiedt R, Coers J, Ziegler S, Wiestner A, Hao-Shen H, Bornmann C, Schenkel J, Karakhanova S, de Sauvage FJ, Jackson CW, Skoda RC. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 2009;113:1768-1777.
8. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood 2009;113:1778-1785.
9. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood 1999;94:2555-2561.
10. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-580.
11. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869-1871.
12. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
13. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
14. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
15. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714-3719.
16. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001;8:1327-1338.
17. Tong W, Sulahian R, Gross AW, Hendon N, Lodish HF, Huang LJ. The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms. J Biol Chem 2006;281:38930-38940.
18. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011;334:1081-1086.
19. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 2011;334:1086-1090.
20. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 2005;7:766-772.
21. Nakatsukasa K, Brodsky JL. The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic 2008;9:861-870.
22. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK, Momoi T. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 2007;16:618-629.
23. Gee HY, Noh SH, Tang BL, Kim KH, Lee MG. Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway. Cell 2011;146:746-760.
24. Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J 2011;30:4701-4711.
25. Bruns C, McCaffery JM, Curwin AJ, Duran JM, Malhotra V. Biogenesis of a novel compartment for autophagosome-mediated unconventional protein secretion. J Cell Biol 2011;195:979-992.
26. Hayashi-Nishino M, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat Cell Biol 2009;11:1433-1437.
27. Deretic V, Jiang S, Dupont N. Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. Trends Cell Biol 2012;22:397-406.
28. Zhang M, Schekman R. Cell biology. Unconventional secretion, unconventional solutions. Science 2013;340:559-561.
29. Cleyrat C, Vilaine M, Boissinot M, Girodon F, Steinkamp MP, Dobo I, Lippert É, Corre I, Wilson BS, Hermouet S. Surface expression of Mpl: aberrant Mpl trafficking in myeloproliferative neoplasms is linked to insufficient expression of wildtype Jak2. Blood (ASH Annual Meeting Abstracts) 2011;118:2820.
30. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001;20:6188-6195.
31. Porteu F, Rouyez MC, Cocault L, Benit L, Charon M, Picard F, Gisselbrecht S, Souyri M, Dusanter-Fourt I. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin. Mol Cell Biol 1996;16:2473-2482.
32. Wilson BS, Pfeiffer JR, Smith AJ, Oliver JM, Oberdorf JA, Wojcikiewicz RJ. Calcium-dependent clustering of inositol 1, 4, 5-trisphosphate receptors. Mol Biol Cell 1998;9:1465-1478.
33. Fader CM, Sanchez D, Furlan M, Colombo MI. Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. Traffic 2008;9:230-250.
34. Shu X, Lev-Ram V, Deerinck TJ, Qi Y, Ramko EB, Davidson MW, Jin Y, Ellisman MH, Tsien RY. A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. PLoS Biol 2011;9:e1001041.
35. Kraft C, Martens S. Mechanisms and regulation of autophagosome formation. Curr Opin Cell Biol 2012;24:496-501.
36. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007;3:452-460.
37. Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood 2012;119:4625-4635.
38. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol 2002;3:122-131.
39. Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003;278:20083-20090.
40. Musiwaro P, Smith M, Manifava M, Walker SA, Ktistakis NT. Characteristics and requirements of basal autophagy in HEK 293 cells. Autophagy 2013;9:1407-1417.
41. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000;275:992-998.
42. Tanemura M, Ohmura Y, Deguchi T, Machida T, Tsukamoto R, Wada H, Kobayashi S, Marubashi S, Eguchi H, Ito T, Nagano H, Mori M, Doki Y. Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. Am J Transplant 2012;12:102-114.
43. Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon HU. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun 2013;4:2130.
44. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003;4:181-191.
45. Kostova Z, Wolf DH. For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J 2003;22:2309-2317.
46. McCracken AA, Brodsky JL. Evolving questions and paradigm shifts in endoplasmic-reticulum-associated degradation (ERAD). Bioessays 2003;25:868-877.
47. Katayama H, Kogure T, Mizushima N, Yoshimori T, Miyawaki A. A sensitive and quantitative technique for detecting autophagic events based on lysosomal delivery. Chem Biol 2011;18:1042-1052.
48. Pfeffer SR. Unconventional secretion by autophagosome exocytosis. J Cell Biol 2010;188:451-452.
49. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009;10:148-155.
50. Cadwell K, Patel KK, Komatsu M. Virgin HWt, Stappenbeck TS. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy 2009;5:250-252.
51. DeSelm CJ, Miller BC, Zou W, Beatty WL, van Meel E, Takahata Y, Klumperman J, Tooze SA, Teitelbaum SL, Virgin HW. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev Cell 2011;21:966-974.
52. Ushio H, Ueno T, Kojima Y, Komatsu M, Tanaka S, Yamamoto A, Ichimura Y, Ezaki J, Nishida K, Komazawa-Sakon S, Niyonsaba F, Ishii T, Yanagawa T, Kominami E, Ogawa H, et al. Crucial role for autophagy in degranulation of mast cells. J Allergy Clin Immunol 2011;127:1267-1276, e1266.
53. Zoppino FC, Militello RD, Slavin I, Alvarez C, Colombo MI. Autophagosome formation depends on the small GTPase Rab1 and functional ER exit sites. Traffic 2010;11:1246-1261.
54. Luo Y, McDonald K, Hanrahan JW. Trafficking of immature DeltaF508-CFTR to the plasma membrane and its detection by biotinylation. Biochem J 2009;419:211-219, 212 p following 219.
55. Giuliani F, Grieve A, Rabouille C. Unconventional secretion: a stress on GRASP. Curr Opin Cell Biol 2011;23:498-504.
56. Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, Baumann WT, Tyson JJ, Xuan J, Wang Y, Warri A, Shajahan AN. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res 2012;72:1321-1331.
57. Albu RI, Constantinescu SN. Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. Front Endocrinol (Lausanne) 2011;2:71.
58. Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. Oncogene 2011;30:990-1001.
59. Zhao L, Dong H, Zhang CC, Kinch L, Osawa M, Iacovino M, Grishin NV, Kyba M, Huang LJ. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 2009;284:26988-26998.
60. Staerk J, Defour JP, Pecquet C, Leroy E, Antoine-Poirel H, Brett I, Itaya M, Smith SO, Vainchenker W, Constantinescu SN. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J 2011;30:4398-4413.
61. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, Giraudier S, Constantinescu SN. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010;116:437-445.
62. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913-3915.
63. Chen D, Bernstein AM, Lemons PP, Whiteheart SW. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood 2000;95:921-929.
64. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119:2721-2730.
65. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
66. Santos FP, Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev 2011;25:53-63.
67. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, Issa JP, Hermouet S. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 2010;24:1069-1073.
68. Girodon F, Steinkamp MP, Cleyrat C, Hermouet S, Wilson BS. Confocal imaging studies cast doubt on nuclear localization of JAK2V617F. Blood 2011;118:2633-2634.
69. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51-59.
70. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-5728.